First patient receives JANX014 dose in Janux’s trial for mCRPC
The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance